SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2019
Commission File Number: 001-38480
(Name of registrant)
130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
[ ] Form 20-F [ X ] Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Date: May 15, 2019||By:||/s/ Pierre Labbé|
|Name: Pierre Labbé|
|Title: Chief Financial Officer|
Form 6-K Exhibit Index
|99.1||News Release dated May 14, 2019. IMV Inc. to Present at Upcoming Investor Conferences|
FOR IMMEDIATE RELEASE
IMV Inc. to Present at Upcoming Investor Conferences
Dartmouth, Nova Scotia, May 14, 2019 – IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that IMV Chief Executive Officer Frederic Ors will present at the following investor conferences in May:
RBC Capital Markets Global Healthcare Conference
Date: Tuesday, May 21, 2019
Time: 1:35 p.m. ET
Location: The InterContinental New York Barclay Hotel, New York, NY
National Bank Financials’ 9th Annual Quebec Conference
Date: Wednesday, May 29, 2019
Time: 9:50 a.m. ET
Location: Museum Room, Shangri-la Hotel, Toronto, Ontario
China Bio-Partnering Forum
Date: Thursday, May 30, 2019
Time: 1:40 P.M. CT
Location: Renaissance Schaumburg Convention Center Hotel, Chicago, IL
A copy of each meeting’s presentation will be available in the events and presentations section of IMV’s website. A live webcast of IMV’s presentation at the RBC Capital Markets conference will also be available and archived for 90 days on the events and presentations webpage.
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Connect at www.imv-inc.com.
Source: IMV Inc.
Marc Jasmin, IMV Senior Director, Investor Relations and Communications
O: (902) 492-1819 ext : 1042
M: (514) 617-9481 E: firstname.lastname@example.org
Andrea Cohen, Sam Brown Inc.
T: (917) 209-7163 E: email@example.com